<i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial
This study investigated whether <i>Lactobacillus paragasseri</i> SBT2055 (LG2055) activates plasmacytoid dendritic cells (pDCs) and suppresses common cold symptoms in healthy adults. Cell-based experiments showed that a LG2055 treatment upregulated CD86 and HLA-DR expression in pDCs, ind...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/20/4458 |
| _version_ | 1797572681835479040 |
|---|---|
| author | Eiji Kobatake Yoshitaka Iwama Toshinobu Arai Yuki Tsukisaka Toshihide Kabuki |
| author_facet | Eiji Kobatake Yoshitaka Iwama Toshinobu Arai Yuki Tsukisaka Toshihide Kabuki |
| author_sort | Eiji Kobatake |
| collection | DOAJ |
| description | This study investigated whether <i>Lactobacillus paragasseri</i> SBT2055 (LG2055) activates plasmacytoid dendritic cells (pDCs) and suppresses common cold symptoms in healthy adults. Cell-based experiments showed that a LG2055 treatment upregulated CD86 and HLA-DR expression in pDCs, indicating that LG2055 activates pDCs in vitro. In a subsequent randomized, double-blind, placebo-controlled, parallel-group comparative trial, 200 participants were randomly divided into two groups and consumed three capsules with or without LG2055 once daily for 12 weeks. The primary outcome was the score on a daily physical health questionnaire survey of common cold symptoms. Three participants discontinued the trial and six participants were excluded from the analysis, thus 191 participants (95 in the LG2055 group and 96 in the placebo group) were analyzed. The LG2055 group showed a significantly higher ratio of “without symptoms” responses for runny nose, plugged nose, sneezing, sore throat, hoarseness, and chill than the placebo group. Furthermore, a stratified analysis revealed that LG2055 intake enhanced CD86 and HLA-DR expression in the pDCs of the participants with low secretion rates of salivary secretory immunoglobulin A. These data suggest that LG2055 suppresses the subjective symptoms of the common cold by activating pDCs and improving the host’s immune system in healthy adults, especially in immune-weakened individuals (UMIN000049183). |
| first_indexed | 2024-03-10T20:59:53Z |
| format | Article |
| id | doaj.art-a9c29d85012f4e24b4e9203d43f02e5d |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-10T20:59:53Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-a9c29d85012f4e24b4e9203d43f02e5d2023-11-19T17:39:13ZengMDPI AGNutrients2072-66432023-10-011520445810.3390/nu15204458<i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative TrialEiji Kobatake0Yoshitaka Iwama1Toshinobu Arai2Yuki Tsukisaka3Toshihide Kabuki4Milk Science Research Institute, MEGMILK SNOW BRAND Co., Ltd., Kawagoe 350-1165, JapanNihonbashi Cardiology Clinic, Tokyo 103-0001, JapanResearch and Development Planning Department, MEGMILK SNOW BRAND Co., Ltd., Tokyo 160-8575, JapanKSO Corporation, Tokyo 105-0023, JapanMilk Science Research Institute, MEGMILK SNOW BRAND Co., Ltd., Kawagoe 350-1165, JapanThis study investigated whether <i>Lactobacillus paragasseri</i> SBT2055 (LG2055) activates plasmacytoid dendritic cells (pDCs) and suppresses common cold symptoms in healthy adults. Cell-based experiments showed that a LG2055 treatment upregulated CD86 and HLA-DR expression in pDCs, indicating that LG2055 activates pDCs in vitro. In a subsequent randomized, double-blind, placebo-controlled, parallel-group comparative trial, 200 participants were randomly divided into two groups and consumed three capsules with or without LG2055 once daily for 12 weeks. The primary outcome was the score on a daily physical health questionnaire survey of common cold symptoms. Three participants discontinued the trial and six participants were excluded from the analysis, thus 191 participants (95 in the LG2055 group and 96 in the placebo group) were analyzed. The LG2055 group showed a significantly higher ratio of “without symptoms” responses for runny nose, plugged nose, sneezing, sore throat, hoarseness, and chill than the placebo group. Furthermore, a stratified analysis revealed that LG2055 intake enhanced CD86 and HLA-DR expression in the pDCs of the participants with low secretion rates of salivary secretory immunoglobulin A. These data suggest that LG2055 suppresses the subjective symptoms of the common cold by activating pDCs and improving the host’s immune system in healthy adults, especially in immune-weakened individuals (UMIN000049183).https://www.mdpi.com/2072-6643/15/20/4458<i>Lactobacillus paragasseri</i> SBT2055clinical studysubjective symptomscommon coldplasmacytoid dendritic cells |
| spellingShingle | Eiji Kobatake Yoshitaka Iwama Toshinobu Arai Yuki Tsukisaka Toshihide Kabuki <i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial Nutrients <i>Lactobacillus paragasseri</i> SBT2055 clinical study subjective symptoms common cold plasmacytoid dendritic cells |
| title | <i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial |
| title_full | <i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial |
| title_fullStr | <i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial |
| title_full_unstemmed | <i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial |
| title_short | <i>Lactobacillus paragasseri</i> SBT2055 Activates Plasmacytoid Dendritic Cells and Improves Subjective Symptoms of Common Cold in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Comparative Trial |
| title_sort | i lactobacillus paragasseri i sbt2055 activates plasmacytoid dendritic cells and improves subjective symptoms of common cold in healthy adults a randomized double blind placebo controlled parallel group comparative trial |
| topic | <i>Lactobacillus paragasseri</i> SBT2055 clinical study subjective symptoms common cold plasmacytoid dendritic cells |
| url | https://www.mdpi.com/2072-6643/15/20/4458 |
| work_keys_str_mv | AT eijikobatake ilactobacillusparagasseriisbt2055activatesplasmacytoiddendriticcellsandimprovessubjectivesymptomsofcommoncoldinhealthyadultsarandomizeddoubleblindplacebocontrolledparallelgroupcomparativetrial AT yoshitakaiwama ilactobacillusparagasseriisbt2055activatesplasmacytoiddendriticcellsandimprovessubjectivesymptomsofcommoncoldinhealthyadultsarandomizeddoubleblindplacebocontrolledparallelgroupcomparativetrial AT toshinobuarai ilactobacillusparagasseriisbt2055activatesplasmacytoiddendriticcellsandimprovessubjectivesymptomsofcommoncoldinhealthyadultsarandomizeddoubleblindplacebocontrolledparallelgroupcomparativetrial AT yukitsukisaka ilactobacillusparagasseriisbt2055activatesplasmacytoiddendriticcellsandimprovessubjectivesymptomsofcommoncoldinhealthyadultsarandomizeddoubleblindplacebocontrolledparallelgroupcomparativetrial AT toshihidekabuki ilactobacillusparagasseriisbt2055activatesplasmacytoiddendriticcellsandimprovessubjectivesymptomsofcommoncoldinhealthyadultsarandomizeddoubleblindplacebocontrolledparallelgroupcomparativetrial |